Biogen Inc and partner Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has extended the review period for their experimental Alzheimer’s disease treatment by three months.
US FDA extends review period for Biogen’s Alzheimer’s drug
- Advertisement -
